{"id":"NCT03072238","sponsor":"Hoffmann-La Roche","briefTitle":"Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-30","primaryCompletion":"2020-03-16","completion":"2024-04-24","firstPosted":"2017-03-07","resultsPosted":"2023-04-10","lastUpdate":"2025-06-06"},"enrollment":1101,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Ipatasertib","otherNames":[]},{"type":"DRUG","name":"Abiraterone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Prednisone/Prednisolone","otherNames":[]}],"arms":[{"label":"Placebo + Abiraterone","type":"ACTIVE_COMPARATOR"},{"label":"Ipatasertib + Abiraterone","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).","primaryOutcome":{"measure":"Investigator-assessed Radiographic Progression-free Survival (rPFS), Per Prostate Cancer Working Group 3 (PCWG3) Criteria in Phosphatase and Tensin Homolog (PTEN) Loss Population","timeFrame":"Up to approximately 32 months","effectByArm":[{"arm":"Pbo + Abi","deltaMin":16.5,"sd":null},{"arm":"Ipat + Abi","deltaMin":18.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0335"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":176,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Costa Rica","Denmark","France","Greece","Hungary","Ireland","Israel","Italy","Japan","Mexico","Norway","Poland","Portugal","Russia","South Korea","Spain","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["36697317","36305957","34246347"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":158,"n":546},"commonTop":["Diarrhoea","Hyperglycaemia","Fatigue","Back pain","Nausea"]}}